Versant Capital Management
CLPT icon

Versant Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Versant Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$34.4K Sell
2,820
-638
-18% -$9.6K ﹤0.01% 1664
2026
Q2 		$61.7K Buy
3,458
+3,397
+5,569% +$42.4K 0.01% 1217
2026
Q1 		$555 Buy
+61
New +$770 ﹤0.01% 2718

Other funds holding CLPT

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Lane Generational
Lane Generational Dover, Massachusetts $111M AUM 16.63% 1-Year Est. Return
Pekin Hardy Strauss
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return
Compass Financial Management
Compass Financial Management Tampa, Florida $926M AUM
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Parsons Capital Management
Parsons Capital Management Providence, Rhode Island $2.29B AUM 21.99% 1-Year Est. Return
Taylor Frigon Capital Management
Taylor Frigon Capital Management Scottsdale, Arizona $197M AUM 35.01% 1-Year Est. Return

Versant Capital Management's CLPT Position: Q3 2026 in Review

Versant Capital Management reduced its ClearPoint Neuro (CLPT) stake by 18% in Q3 2026, selling an estimated $9.6K and leaving 2,820 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Versant Capital Management first reported a position in CLPT in Q1 2026 and has held it in 3 quarters since. The position peaked at $61.7K in Q2 2026. 70 funds tracked by Wall St. Rank hold CLPT as of Q3 2026.

  • Versant Capital Management held 2,820 shares of ClearPoint Neuro worth $34.4K as of Q3 2026.
  • Versant Capital Management sold 638 ClearPoint Neuro shares in Q3 2026, an estimated $9.6K.
  • ClearPoint Neuro made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1664 holding.
  • Versant Capital Management first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 3 quarters since.
  • Versant Capital Management's ClearPoint Neuro position peaked at $61.7K in Q2 2026.
  • 70 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.